Glucagon response study for Obesity

Phase-Based Progress Estimates
Mayo Clinic in Rochester, Rochester, MN
Obesity+2 More
Glucagon response study - Drug
All Sexes
What conditions do you have?

Study Summary

Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid catabolism and EGP interact with hepatic lipid metabolism in lean and obese subjects with and without T2DM (and with varying degrees of hepatic steatosis).

Eligible Conditions

  • Obesity
  • Type2diabetes
  • (NAFLD)

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 240 minutes of study

240 minutes of study
Effect of Diabetes on amino-acid catabolism
Rate of Amino acid catabolism in the presence / absence of glucagon

Trial Safety

Trial Design

3 Treatment Groups

Healthy Adults
1 of 3
Obese Adults
1 of 3
Adults with Type 2 Diabetes
1 of 3
Experimental Treatment

60 Total Participants · 3 Treatment Groups

Primary Treatment: Glucagon response study · No Placebo Group · Phase 1 & 2

Healthy Adults
Experimental Group · 1 Intervention: Glucagon response study · Intervention Types: Drug
Obese Adults
Experimental Group · 1 Intervention: Glucagon response study · Intervention Types: Drug
Adults with Type 2 Diabetes
Experimental Group · 1 Intervention: Glucagon response study · Intervention Types: Drug

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 240 minutes of study
Closest Location: Mayo Clinic in Rochester · Rochester, MN
Photo of Rochester 1Photo of Rochester 2Photo of Rochester 3
2021First Recorded Clinical Trial
38 TrialsResearching Obesity
503 CompletedClinical Trials

Who is running the clinical trial?

Adrian VellaLead Sponsor
8 Previous Clinical Trials
175 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to participate in the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.